JP2016511753A5 - - Google Patents

Download PDF

Info

Publication number
JP2016511753A5
JP2016511753A5 JP2015555661A JP2015555661A JP2016511753A5 JP 2016511753 A5 JP2016511753 A5 JP 2016511753A5 JP 2015555661 A JP2015555661 A JP 2015555661A JP 2015555661 A JP2015555661 A JP 2015555661A JP 2016511753 A5 JP2016511753 A5 JP 2016511753A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
hepe
present
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015555661A
Other languages
English (en)
Japanese (ja)
Other versions
JP6363104B2 (ja
JP2016511753A (ja
Filing date
Publication date
Priority claimed from GBGB1301626.6A external-priority patent/GB201301626D0/en
Application filed filed Critical
Publication of JP2016511753A publication Critical patent/JP2016511753A/ja
Publication of JP2016511753A5 publication Critical patent/JP2016511753A5/ja
Application granted granted Critical
Publication of JP6363104B2 publication Critical patent/JP6363104B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015555661A 2013-01-30 2014-01-24 15−ohepaを含む組成物および同組成物を使用する方法 Expired - Fee Related JP6363104B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1301626.6 2013-01-30
GBGB1301626.6A GB201301626D0 (en) 2013-01-30 2013-01-30 Composition comprising 15-OHEPA and methods of using the same
PCT/EP2014/051455 WO2014118097A1 (en) 2013-01-30 2014-01-24 Compositions comprising 15-ohepa and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018121494A Division JP2018172409A (ja) 2013-01-30 2018-06-27 15−ohepaを含む組成物および同組成物を使用する方法

Publications (3)

Publication Number Publication Date
JP2016511753A JP2016511753A (ja) 2016-04-21
JP2016511753A5 true JP2016511753A5 (https=) 2017-02-23
JP6363104B2 JP6363104B2 (ja) 2018-07-25

Family

ID=47891001

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015555661A Expired - Fee Related JP6363104B2 (ja) 2013-01-30 2014-01-24 15−ohepaを含む組成物および同組成物を使用する方法
JP2018121494A Pending JP2018172409A (ja) 2013-01-30 2018-06-27 15−ohepaを含む組成物および同組成物を使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018121494A Pending JP2018172409A (ja) 2013-01-30 2018-06-27 15−ohepaを含む組成物および同組成物を使用する方法

Country Status (27)

Country Link
US (6) US20150224076A1 (https=)
EP (2) EP2762143B1 (https=)
JP (2) JP6363104B2 (https=)
KR (6) KR20230047201A (https=)
CN (2) CN111214464A (https=)
AU (2) AU2014211628B2 (https=)
BR (1) BR112015018270A2 (https=)
CA (1) CA2897343C (https=)
CY (1) CY1117209T1 (https=)
DK (1) DK2762143T3 (https=)
ES (2) ES2564025T3 (https=)
GB (1) GB201301626D0 (https=)
HR (1) HRP20160203T1 (https=)
HU (1) HUE026901T2 (https=)
IL (3) IL239893A (https=)
MX (2) MX364646B (https=)
NZ (1) NZ709803A (https=)
PH (1) PH12015501582B1 (https=)
PL (1) PL2762143T3 (https=)
PT (1) PT2762143E (https=)
RS (1) RS54584B1 (https=)
RU (2) RU2018136872A (https=)
SG (2) SG11201505457PA (https=)
SI (1) SI2762143T1 (https=)
SM (1) SMT201600069B (https=)
WO (1) WO2014118097A1 (https=)
ZA (2) ZA201505018B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
JP2016538288A (ja) 2013-11-15 2016-12-08 ディグニティ サイエンシス リミテッド 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
EP3091959A4 (en) * 2014-01-10 2017-09-20 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
US20180008567A1 (en) * 2015-01-16 2018-01-11 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
ES2980790T3 (es) 2015-04-28 2024-10-03 Basf As Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica
MA47141A (fr) * 2015-05-13 2019-11-06 Ds Biopharma Ltd Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
ES2851525T3 (es) * 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
CA3129008A1 (en) * 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
IL308604B2 (en) 2017-12-06 2025-08-01 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN115215725A (zh) * 2021-04-15 2022-10-21 宋晓瑜 一种制备乙酸薰衣草酯及薰衣草醇的方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
JPH09505562A (ja) 1993-10-01 1997-06-03 アール.ピー.シェーラー コーポレイション 香料を小分けして提供する方法および組成物
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
EP1762557B1 (en) 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
ATE291910T1 (de) 2001-05-30 2005-04-15 Laxdale Ltd Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen
CN1250230C (zh) * 2001-09-30 2006-04-12 中国药品生物制品检定所 海狗油作为制备治脂肪肝药的应用
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
EP1711173A2 (en) 2003-12-31 2006-10-18 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
WO2005102309A2 (en) 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
AU2005262392A1 (en) 2004-07-01 2006-01-19 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating eye disorders and conditions
WO2007081773A2 (en) * 2006-01-05 2007-07-19 Reliant Pharmaceuticals, Inc Treatment of fatty liver
EP3285072B1 (en) 2006-08-08 2020-04-15 Metabolon, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
WO2008126363A1 (ja) * 2007-03-30 2008-10-23 Kowa Company, Ltd. 脂肪肝又は非アルコール性脂肪性肝炎の予防及び/又は治療のための医薬
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
US20110105510A1 (en) * 2008-06-17 2011-05-05 Hiroshi Ishikawa Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
WO2010095706A1 (ja) * 2009-02-20 2010-08-26 国立大学法人東京大学 新規抗炎症性化合物
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
JP5909183B2 (ja) * 2010-08-19 2016-04-26 国立大学法人 東京大学 オメガ3系脂肪酸由来の新規抗炎症性代謝物
WO2012031125A2 (en) 2010-09-01 2012-03-08 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
RU2014119948A (ru) 2011-10-19 2015-11-27 Дигнити Сайенсиз Лимитед ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ DGLA И/ИЛИ 15-HETrE, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2015500639A (ja) 2011-11-29 2015-01-08 ディグニティ サイエンシス リミテッド 20−炭素脂肪酸を含む組成物ならびにその製造方法および使用方法
RS57777B1 (sr) 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
DK2858496T3 (da) * 2012-05-10 2023-07-24 Solutex Na Llc Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
ES2851525T3 (es) * 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
CA3129008A1 (en) 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same

Similar Documents

Publication Publication Date Title
JP2016511753A5 (https=)
JP2017513836A5 (https=)
HRP20160203T1 (hr) Pripravci koji sadrže 15-hepe i postupci njihove upotrebe
RU2018114447A (ru) Введение дейтерированных усилителей cftr
JP2015143248A5 (https=)
RU2018133298A (ru) Способы применения агонистов fxr
CO7240414A2 (es) Preparación y usos de ácido obeticólico
JP2017505285A5 (https=)
JP2014129360A5 (https=)
HRP20192299T1 (hr) Liječenje nafld i nash
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
JP2014218522A5 (https=)
JP2009530398A5 (https=)
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
JP2016510326A5 (https=)
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
SG10201407013QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
JP2017505809A5 (https=)
JP2015510916A5 (https=)
RU2019110980A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
RU2016145066A (ru) Композиция для предотвращения или лечения жировых болезней печени
JP2018537513A5 (https=)
BR112015016184A2 (pt) derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral